Darolutamide causes the binding of AR to genome to be greatly reduced, which strongly inhibits the activation of normal enhancer and super-enhancers, and then hinders several downstream pathways which are very important for prostate cancer proliferation. This evidence concerns the gene AR and prostate carcinoma.